Ignite Creation Date:
2025-12-25 @ 4:55 AM
Ignite Modification Date:
2025-12-26 @ 3:55 AM
Study NCT ID:
NCT03502018
Status:
COMPLETED
Last Update Posted:
2023-11-18
First Post:
2018-03-27
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Hip Fracture Exparel Administration Trial Capsule During Hemiarthroplasty
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2023-10-31', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D005265', 'term': 'Femoral Neck Fractures'}], 'ancestors': [{'id': 'D006620', 'term': 'Hip Fractures'}, {'id': 'D005264', 'term': 'Femoral Fractures'}, {'id': 'D050723', 'term': 'Fractures, Bone'}, {'id': 'D014947', 'term': 'Wounds and Injuries'}, {'id': 'D025981', 'term': 'Hip Injuries'}, {'id': 'D007869', 'term': 'Leg Injuries'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D012965', 'term': 'Sodium Chloride'}], 'ancestors': [{'id': 'D002712', 'term': 'Chlorides'}, {'id': 'D006851', 'term': 'Hydrochloric Acid'}, {'id': 'D017606', 'term': 'Chlorine Compounds'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D017670', 'term': 'Sodium Compounds'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'kkang@maimonidesmed.org', 'phone': '718-283-8805', 'title': 'Dr. Kevin Kang', 'organization': 'Maimonides Medical Center'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': 'Adverse event data was collected from the date of surgery until the 30 days postoperatively from 2018 to 2023', 'eventGroups': [{'id': 'EG000', 'title': 'Saline', 'description': 'This arm will receive Saline along with Bupivacaine\n\nSaline: Saline injection used as control', 'otherNumAtRisk': 25, 'deathsNumAtRisk': 25, 'otherNumAffected': 0, 'seriousNumAtRisk': 25, 'deathsNumAffected': 1, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Bupivacaine Liposome', 'description': 'This arm will receive Exparel along with Bupivacaine\n\nBupivacaine liposome: A long-acting liposomal bupivacaine', 'otherNumAtRisk': 25, 'deathsNumAtRisk': 25, 'otherNumAffected': 0, 'seriousNumAtRisk': 25, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Post-operative Pain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '25', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Saline', 'description': 'This arm will receive Saline along with Bupivacaine\n\nSaline: Saline injection used as control'}, {'id': 'OG001', 'title': 'Bupivacaine Liposome', 'description': 'This arm will receive Exparel along with Bupivacaine\n\nBupivacaine liposome: A long-acting liposomal bupivacaine'}], 'classes': [{'categories': [{'measurements': [{'value': '3.29', 'spread': '2.66', 'groupId': 'OG000'}, {'value': '2.64', 'spread': '2.27', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '4hrs after surgery', 'description': 'Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Post-operative Pain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '25', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Saline', 'description': 'This arm will receive Saline along with Bupivacaine\n\nSaline: Saline injection used as control'}, {'id': 'OG001', 'title': 'Bupivacaine Liposome', 'description': 'This arm will receive Exparel along with Bupivacaine\n\nBupivacaine liposome: A long-acting liposomal bupivacaine'}], 'classes': [{'categories': [{'measurements': [{'value': '3.04', 'spread': '1.64', 'groupId': 'OG000'}, {'value': '2.12', 'spread': '1.79', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '8hrs after surgery', 'description': 'Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Post-operative Pain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '25', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Saline', 'description': 'This arm will receive Saline along with Bupivacaine\n\nSaline: Saline injection used as control'}, {'id': 'OG001', 'title': 'Bupivacaine Liposome', 'description': 'This arm will receive Exparel along with Bupivacaine\n\nBupivacaine liposome: A long-acting liposomal bupivacaine'}], 'classes': [{'categories': [{'measurements': [{'value': '2.42', 'spread': '2.19', 'groupId': 'OG000'}, {'value': '2.08', 'spread': '2.72', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '12hrs after surgery', 'description': 'Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Post-operative Pain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '25', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Saline', 'description': 'This arm will receive Saline along with Bupivacaine\n\nSaline: Saline injection used as control'}, {'id': 'OG001', 'title': 'Bupivacaine Liposome', 'description': 'This arm will receive Exparel along with Bupivacaine\n\nBupivacaine liposome: A long-acting liposomal bupivacaine'}], 'classes': [{'categories': [{'measurements': [{'value': '2.58', 'spread': '2.86', 'groupId': 'OG000'}, {'value': '2.00', 'spread': '2.48', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '24hrs after surgery', 'description': 'Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Post-operative Pain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '25', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Saline', 'description': 'This arm will receive Saline along with Bupivacaine\n\nSaline: Saline injection used as control'}, {'id': 'OG001', 'title': 'Bupivacaine Liposome', 'description': 'This arm will receive Exparel along with Bupivacaine\n\nBupivacaine liposome: A long-acting liposomal bupivacaine'}], 'classes': [{'categories': [{'measurements': [{'value': '2.71', 'spread': '3.10', 'groupId': 'OG000'}, {'value': '2.04', 'spread': '2.69', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '48hrs after surgery', 'description': 'Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Time to Ambulation', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '25', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Saline', 'description': 'This arm will receive Saline along with Bupivacaine\n\nSaline: Saline injection used as control'}, {'id': 'OG001', 'title': 'Bupivacaine Liposome', 'description': 'This arm will receive Exparel along with Bupivacaine\n\nBupivacaine liposome: A long-acting liposomal bupivacaine'}], 'classes': [{'categories': [{'measurements': [{'value': '1.44', 'spread': '0.82', 'groupId': 'OG000'}, {'value': '1.12', 'spread': '0.53', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '24 and 48 hours after surgery', 'description': 'Measure of time to ambulation with physical therapy', 'unitOfMeasure': 'Days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Postoperative Total Morphine Equivalent', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '25', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Saline', 'description': 'This arm will receive Saline along with Bupivacaine\n\nSaline: Saline injection used as control'}, {'id': 'OG001', 'title': 'Bupivacaine Liposome', 'description': 'This arm will receive Exparel along with Bupivacaine\n\nBupivacaine liposome: A long-acting liposomal bupivacaine'}], 'classes': [{'categories': [{'measurements': [{'value': '9.98', 'spread': '10.638927', 'groupId': 'OG000'}, {'value': '12.09', 'spread': '9.65', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '48 hours after surgery', 'description': 'Total dose in milligrams of opiates measured in total morphine equivalents. This was measured by calculating the sum of total morphine equivalents administered within 48 hours postoperatively. Assessed at 12, 24, 36, 48 hours after surgery, total postoperative total morphine equivalents at 48 hours after surgery reported', 'unitOfMeasure': 'Morphine Equivalent', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Delirium Scale Measurements', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '25', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Saline', 'description': 'This arm will receive Saline along with Bupivacaine\n\nSaline: Saline injection used as control'}, {'id': 'OG001', 'title': 'Bupivacaine Liposome', 'description': 'This arm will receive Exparel along with Bupivacaine\n\nBupivacaine liposome: A long-acting liposomal bupivacaine'}], 'classes': [{'categories': [{'title': 'At 24 Hours', 'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}, {'title': 'At 48 Hours', 'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}, {'title': 'No Delirium', 'measurements': [{'value': '24', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '24 and 48 hours after surgery', 'description': 'Assessment of post-operative delirium based on Short Confusion Assessment Method', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Length of Stay', 'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'OG000'}, {'value': '25', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Saline', 'description': 'This arm will receive Saline along with Bupivacaine\n\nSaline: Saline injection used as control'}, {'id': 'OG001', 'title': 'Bupivacaine Liposome', 'description': 'This arm will receive Exparel along with Bupivacaine\n\nBupivacaine liposome: A long-acting liposomal bupivacaine'}], 'classes': [{'categories': [{'measurements': [{'value': '3.88', 'spread': '2.13', 'groupId': 'OG000'}, {'value': '3.92', 'spread': '1.44', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '7 days from day of admission', 'description': 'Total days until discharge from hospital', 'unitOfMeasure': 'Days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Saline', 'description': 'This arm will receive Saline along with Bupivacaine\n\nSaline: Saline injection used as control'}, {'id': 'FG001', 'title': 'Bupivacaine Liposome', 'description': 'This arm will receive Exparel along with Bupivacaine\n\nBupivacaine liposome: A long-acting liposomal bupivacaine'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '25'}, {'groupId': 'FG001', 'numSubjects': '25'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '24'}, {'groupId': 'FG001', 'numSubjects': '25'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '24', 'groupId': 'BG000'}, {'value': '25', 'groupId': 'BG001'}, {'value': '49', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Saline', 'description': 'This arm will receive Saline along with Bupivacaine\n\nSaline: Saline injection used as control'}, {'id': 'BG001', 'title': 'Bupivacaine Liposome', 'description': 'This arm will receive Exparel along with Bupivacaine\n\nBupivacaine liposome: A long-acting liposomal bupivacaine'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '24', 'groupId': 'BG000'}, {'value': '25', 'groupId': 'BG001'}, {'value': '49', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '20', 'groupId': 'BG000'}, {'value': '18', 'groupId': 'BG001'}, {'value': '38', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '16', 'groupId': 'BG000'}, {'value': '23', 'groupId': 'BG001'}, {'value': '39', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '24', 'groupId': 'BG000'}, {'value': '25', 'groupId': 'BG001'}, {'value': '49', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2017-06-19', 'size': 189245, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2023-10-05T10:46', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR'], 'maskingDescription': 'Participants, Investigator(s), outcome assessors will all be blinded throughout the duration of the trial. Care providers pre- and post- op will be blinded as well, the operative team will not be blinded.'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'There will be a total of 50 patients enrolled in this randomized blinded prospective two arm study. The participants will be randomized into either the control or the EXPAREL treatment group, with 25 patients in each cohort.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 50}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-03-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-10', 'completionDateStruct': {'date': '2023-08-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-10-31', 'studyFirstSubmitDate': '2018-03-27', 'resultsFirstSubmitDate': '2023-10-08', 'studyFirstSubmitQcDate': '2018-04-10', 'lastUpdatePostDateStruct': {'date': '2023-11-18', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2023-10-31', 'studyFirstPostDateStruct': {'date': '2018-04-18', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2023-11-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-08-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Post-operative Pain', 'timeFrame': '4hrs after surgery', 'description': 'Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain'}, {'measure': 'Post-operative Pain', 'timeFrame': '8hrs after surgery', 'description': 'Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain'}, {'measure': 'Post-operative Pain', 'timeFrame': '12hrs after surgery', 'description': 'Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain'}, {'measure': 'Post-operative Pain', 'timeFrame': '24hrs after surgery', 'description': 'Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain'}, {'measure': 'Post-operative Pain', 'timeFrame': '48hrs after surgery', 'description': 'Primary outcome measure will be postoperative visual analogue scale (VAS from 0-10) pain scores. 0 = no pain, 10 = most pain'}], 'secondaryOutcomes': [{'measure': 'Time to Ambulation', 'timeFrame': '24 and 48 hours after surgery', 'description': 'Measure of time to ambulation with physical therapy'}, {'measure': 'Postoperative Total Morphine Equivalent', 'timeFrame': '48 hours after surgery', 'description': 'Total dose in milligrams of opiates measured in total morphine equivalents. This was measured by calculating the sum of total morphine equivalents administered within 48 hours postoperatively. Assessed at 12, 24, 36, 48 hours after surgery, total postoperative total morphine equivalents at 48 hours after surgery reported'}, {'measure': 'Delirium Scale Measurements', 'timeFrame': '24 and 48 hours after surgery', 'description': 'Assessment of post-operative delirium based on Short Confusion Assessment Method'}, {'measure': 'Length of Stay', 'timeFrame': '7 days from day of admission', 'description': 'Total days until discharge from hospital'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Exparel', 'Bupivacaine', 'Intracapsular Fracture of the Femur', 'Femoral Neck Fracture', 'Hip Hemiarthroplasty'], 'conditions': ['Intracapsular Fracture of Femur', 'Femoral Neck Fractures', 'Hip Hemiarthroplasty']}, 'descriptionModule': {'briefSummary': 'This study will examine the efficacy of Liposomal Bupivacaine (Exparel) in hip fracture patients undergoing hip hemiarthroplasty for femoral neck fractures through a posterior approach. Post-operative measures will be assessing pain, overall opiate use, delirium, time-to-ambulation and discharge status.', 'detailedDescription': "Exparel is a long-acting and sustained release formulation of the local anesthetic, bupivacaine HCl. Recent studies have supported its efficacy following total joint arthroplasty, but little is known about Exparel's effectiveness in hip fracture patients. This investigation will study the effects of Exparel on postoperative pain following hip fracture surgery. This is a single center, randomized prospective double blinded study of 50 patients with hip fractures that will have intracapsular hip hemiarthroplasties and are 65 years or older. Twenty-five patients will be treated with intraoperative injections of Exparel. Current standard of care does not include any injection of pain medication during hip hemiarthroplasty. There is no 'standard treatment', but to use multimodal IV and oral analgesia. The control group consisting of the remaining 25 patients will receive 'standard treatment' (which is is multimodal IV and oral analgesia). Therefore, saline is the appropriate placebo and control injection for this study. There are minimal to no risks associated with the injection of saline into the soft tissues about the hip and will take \\<2 minutes to complete. The surgeries will be performed by five surgeons who will use their standard treatment or in the interventional group participants will relieve 20 cc of Exparel diluted with 40 ml 0.25% bupivacaine into the surrounding hip capsule: external rotators, gluteus medius, gluteus minimus, gluteus maximus, tensor fascia lata, vastus lateralis, and subcutaneous tissues.\n\nBoth the patient and the researcher following the patient postoperatively will be blinded. While the treating surgeon will be able to notice the difference between the placebo and Exparel, the outcomes outlined below will be recorded by the blinded Orthopaedic Research Resident who has no clinical responsibilities during his/her year of research and does not participate in operative procedures\n\nThere are two overall aims of this investigation. The first aim is to identify whether Exparel has an impact on postoperative pain and function following open treatment of hip fractures. The hypothesis is that injecting Exparel into the hip capsule and surrounding tissues will decrease narcotic use, and in turn decrease the risk of associated side effects including medically induced delirium, constipation, and decreased alertness. The second aim of the study is focused on examining whether increased pain control leads to better postoperative outcomes? When pain is better controlled via non-narcotic measures, overall patient comfort will improve while sparing cognitive function, decreasing time to ambulation, and accelerating progress with physical therapy. Quicker recovery times will then produce shorter hospital stays, which would yield better overall patient satisfaction and overall improved outcomesPatients with intracapsular hip fractures will undergo hip hemiarthroplasty using a bipolar prosthesis placed via a posterior approach. Primary outcome measures include postoperative visual analogue scale (VAS from 0-10) pain scores at 12, 24, 36, 48 hours after surgery, time to ambulation with physical therapy, need for postoperative total morphine equivalent, and delirium scale measurements. Secondary outcomes measures will compare length of stay, discharge disposition (home or skilled nursing facility), 30-day readmission rates, and adverse events leading to ICU care or reoperation. All patients in both groups will have access to breakthrough pain medication which will either be Immediate acting Oxycodone for moderate to severe pain (pain scale of 4-10, Acetaminophen or Toradol for mild to moderate pain (pain scale of 2-4)."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['OLDER_ADULT'], 'minimumAge': '65 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nMen and women sixty-five years of age and older with isolated intracapsular hip fractures undergoing hemi arthroplasty through a posterior approach with the ability to consent to the study.\n\nExclusion Criteria:\n\nUnder sixty-five years of age, extracapsular hip fracture, suffer from any form of cognitive compromise that leaves them unable to consent, or if they are treated with any surgical modality other than hip hemiarthroplasty.'}, 'identificationModule': {'nctId': 'NCT03502018', 'acronym': 'HEAT', 'briefTitle': 'Hip Fracture Exparel Administration Trial Capsule During Hemiarthroplasty', 'organization': {'class': 'OTHER', 'fullName': 'Maimonides Medical Center'}, 'officialTitle': 'Evaluation of the Efficacy of Exparel Delivered Into the Hip Capsule During Hemiarthroplasty', 'orgStudyIdInfo': {'id': '2016-10-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Saline', 'description': 'This arm will receive Saline along with Bupivacaine', 'interventionNames': ['Drug: Saline']}, {'type': 'EXPERIMENTAL', 'label': 'Bupivacaine liposome', 'description': 'This arm will receive Exparel along with Bupivacaine', 'interventionNames': ['Drug: Bupivacaine liposome']}], 'interventions': [{'name': 'Bupivacaine liposome', 'type': 'DRUG', 'otherNames': ['Exparel'], 'description': 'A long-acting liposomal bupivacaine', 'armGroupLabels': ['Bupivacaine liposome']}, {'name': 'Saline', 'type': 'DRUG', 'otherNames': ['No other names'], 'description': 'Saline injection used as control', 'armGroupLabels': ['Saline']}]}, 'contactsLocationsModule': {'locations': [{'zip': '11219', 'city': 'Brooklyn', 'state': 'New York', 'country': 'United States', 'facility': 'Maimonides Medical Center', 'geoPoint': {'lat': 40.6501, 'lon': -73.94958}}], 'overallOfficials': [{'name': 'Daniel Komlos, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Maimonides Medical Center'}, {'name': 'Kevin Kang, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Maimonides Medical Center'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Maimonides Medical Center', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Primary research investigator', 'investigatorFullName': 'Kevin Kang', 'investigatorAffiliation': 'Maimonides Medical Center'}}}}